Edgewise boosts R&D spending in Q4 with drug milestones in sight

BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based biopharmaceutical company that develops therapies for muscle disease, spent more on research and development and administration during the fourth quarter of the 2025 fiscal year as clinical development activities for a handful of its drug candidates gained steam.

R&D expenses totaled $43.6 million in the most recent period, compared with $37.5 million in the third quarter of 2025, while general and administrative spending rose from $9.4 million to $12.4 over that time.

Edgewise’s net loss the fourth quarter of 2025 was $50.2 million, up from a loss of $40.7 million in the immediately preceding quarter.

“Following strong execution in 2025, we have entered a transformative year,” with development milestones and trial results expected for several of Edgewise’s drug candidates, Edgewise CEO  Kevin Koch said in a prepared statement. “With multiple near-term catalysts and a high-performing team, we are closer than ever to delivering transformative medicines for patients living with serious conditions that still lack adequate treatment options and represent significant unmet medical needs.”

Edgewise’s drug pipeline includes sevasemten, a fast-skeletal myosin inhibitor designed to protect against contractions-induced muscle damage in muscular dystrophies, and EDG-15400, a clinical candidate targeting heart failure.

Share on Facebook on LinkedIn